Insmed, Inc. $INSM Shares Sold by Groupama Asset Managment

Groupama Asset Managment reduced its position in shares of Insmed, Inc. (NASDAQ:INSM) by 96.7% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 13,175 shares of the biopharmaceutical company’s stock after selling 386,825 shares during the period. Groupama Asset Managment’s holdings in Insmed were worth $1,311,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of INSM. Vanguard Group Inc. boosted its holdings in Insmed by 0.3% during the 1st quarter. Vanguard Group Inc. now owns 18,268,122 shares of the biopharmaceutical company’s stock valued at $1,393,675,000 after acquiring an additional 49,149 shares during the period. Price T Rowe Associates Inc. MD lifted its position in shares of Insmed by 1.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 12,923,541 shares of the biopharmaceutical company’s stock worth $985,938,000 after purchasing an additional 219,131 shares in the last quarter. Adage Capital Partners GP L.L.C. boosted its stake in shares of Insmed by 109.2% in the first quarter. Adage Capital Partners GP L.L.C. now owns 3,446,944 shares of the biopharmaceutical company’s stock valued at $262,967,000 after purchasing an additional 1,799,382 shares during the period. Artisan Partners Limited Partnership boosted its stake in shares of Insmed by 3.0% in the second quarter. Artisan Partners Limited Partnership now owns 3,314,341 shares of the biopharmaceutical company’s stock valued at $333,555,000 after purchasing an additional 97,073 shares during the period. Finally, Alliancebernstein L.P. grew its holdings in shares of Insmed by 2.5% in the first quarter. Alliancebernstein L.P. now owns 2,423,513 shares of the biopharmaceutical company’s stock valued at $184,890,000 after purchasing an additional 59,952 shares in the last quarter.

Insider Transactions at Insmed

In other Insmed news, Director Elizabeth M. Anderson sold 10,000 shares of the stock in a transaction that occurred on Friday, November 14th. The shares were sold at an average price of $195.87, for a total value of $1,958,700.00. Following the transaction, the director directly owned 63,729 shares in the company, valued at $12,482,599.23. This represents a 13.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Michael Alexander Smith sold 27,130 shares of the business’s stock in a transaction that occurred on Monday, November 3rd. The stock was sold at an average price of $183.78, for a total transaction of $4,985,951.40. Following the sale, the insider owned 54,902 shares of the company’s stock, valued at $10,089,889.56. This represents a 33.07% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 257,922 shares of company stock valued at $44,556,283 over the last three months. 3.00% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on INSM shares. Cowen reiterated a “buy” rating on shares of Insmed in a report on Thursday, November 20th. TD Cowen increased their price objective on Insmed from $223.00 to $231.00 and gave the company a “buy” rating in a research note on Thursday, November 20th. Evercore ISI reiterated an “outperform” rating and issued a $180.00 target price on shares of Insmed in a report on Wednesday, October 1st. Mizuho set a $196.00 price target on Insmed in a report on Wednesday, October 29th. Finally, Royal Bank Of Canada increased their price target on Insmed from $139.00 to $215.00 and gave the company an “outperform” rating in a research report on Friday, October 31st. Nineteen equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Insmed has an average rating of “Moderate Buy” and a consensus price target of $175.53.

Insmed Stock Up 0.9%

Insmed stock opened at $206.43 on Friday. The stock has a market cap of $44.02 billion, a PE ratio of -36.15 and a beta of 1.05. The company has a debt-to-equity ratio of 0.45, a current ratio of 6.68 and a quick ratio of 6.33. The stock’s fifty day moving average is $173.90 and its two-hundred day moving average is $130.08. Insmed, Inc. has a 1-year low of $60.40 and a 1-year high of $209.77.

Insmed (NASDAQ:INSM) last released its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported ($1.75) EPS for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.40). Insmed had a negative net margin of 259.82% and a negative return on equity of 195.37%. The business had revenue of $142.34 million during the quarter, compared to analysts’ expectations of $114.33 million. During the same quarter in the previous year, the company posted ($1.27) EPS. The company’s revenue was up 52.4% compared to the same quarter last year. Insmed has set its FY 2025 guidance at EPS. On average, sell-side analysts expect that Insmed, Inc. will post -4.56 EPS for the current fiscal year.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.